Akebia Therapeutics (AKBA) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $225.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | VCRE |
|---|---|---|
| Share price | $0.8148 | $8.82 |
| Market cap | $225.79M | $248.41M |
| 1-day change | -6.71% | +1.85% |
| YTD return | -49.39% | — |
| 1-year return | -71.41% | — |
| 5-year return | -71.41% | — |
| EPS (TTM) | $-0.12 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $17.80 |
| 52-week low | $0.814 | $7.88 |
| Distance from 52-week high | -74.54% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.10% | +275.96% |
| Average volume | 6.18M | 16.22K |
| Shares outstanding | 277.11M | 28.16M |
| Employees | 194 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
AKBA vs VCRE FAQ
Which is bigger, Akebia Therapeutics or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $225.79M for Akebia Therapeutics (AKBA).
Are Akebia Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.